Clinical trials: Alcohol-Related Liver Disease
Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD)
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD), Liver Fibrosis
- Trial name
- SOPRANO (NCT05699018)
- Testing
- eLIFT
- Where
- 13 sites in France
- Volunteers
- 1,788 people
- Sponsor
- University Hospital, Angers
Alcohol-related Liver Disease
Genetic Polymorphisms Associated With the Risk of Pancreatitis in Patients With Alcohol Related Cirrhosis.
Alcohol is a known risk factor for both pancreatitis and cirrhosis. However, not all patients with alcohol related cirrhosis develop pancreatitis.
- Trial name
- NCT06763198
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Alcoholic Cirrhosis, Iron Overload
Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis
The main objective of the study is to assess in patients with compensated alcoholic cirrhosis and hepatic iron overload (HIO), as assessed by MRI, the effect of phlebotomy in order to lower and maintain serum ferritin below 50 µg…
- Trial name
- CIRROX (NCT01342705)
- Testing
- phlebotomy
- Where
- 14 sites in France
- Volunteers
- 17 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alcoholic Hepatitis, Infection
N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
Recent data have suggested that monocyte oxidative burst defect is associated with the development of infection in patients with severe alcoholic hepatitis.
- Trial name
- NACAH (NCT03069300)
- Testing
- N-acetyl cysteine (NAC)
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease
Investigating Myosteatosis in Steatotic Liver Diseases
Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities …
- Conditions
- Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease of Mixed Origin (MetALD), Steatotic Liver Diseases
- Trial name
- MYO-SLD (NCT06514300)
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Alcoholic Liver Disease
Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Fermented Protaetia brevitarsis seulensis powder on Alcohol-induced Liver Disease in adults for 8 weeks.
- Trial name
- NCT04320199
- Testing
- Fermented Protaetia brevitarsis seulensis powder group
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pusan National University Yangsan Hospital
Alcoholic Liver Disease
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients.
- Trial name
- NCT03503708
- Testing
- Livitol-70
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Composite Interceptive Med Science
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Alcoholic Liver Diseases
S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease
The study will assess the effect of treatment with formulation containing S-Adenosyl methionine and choline, on patients with alcoholic liver disease.
- Trial name
- NCT03938662
- Testing
- formulation containing S-Adenosyl methionine and choline
- Where
- Serbia
- Volunteers
- 44 people
- Sponsor
- University Clinic Dr Dragisa Misovic-Dedinje
Liver Diseases, Alcoholic
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.
- Trial name
- ALLSTAR (NCT07791043)
- Testing
- Efimosfermin alfa
- Where
- 4 sites in United States, Argentina
- Volunteers
- 274 people
- Sponsor
- GlaxoSmithKline
Adiposity, Fatty Liver
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic…
- Conditions
- Adiposity, Fatty Liver, Alcohol Use Disorder
- Trial name
- GLP-1 RA (NCT06546384)
- Testing
- Semaglutide, Weight reduction recommendations (nutritional and exercise)
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Liver Failure, Liver Diseases, Alcoholic
BRIDGE Device for Post-operative Pain Control
Auricular neurostimulation is a potential novel and non-invasive method of pain control following liver transplantation in a growing patient population with the probability of significant impact on economics and morbidity.
- Conditions
- Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative
- Trial name
- BRIDGE (NCT03265249)
- Testing
- BRIDGE device
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Duke University
ALD - Alcoholic Liver Disease
Comparison of ALD, NASH, and Healthy Control Patients
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in…
- Trial name
- NCT03224949
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Alcoholic Hepatitis
HA35 Moderate Alcoholic Hepatitis (AH) Study
Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement…
- Trial name
- NCT05018481
- Testing
- Sodium Hyaluronate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- The Cleveland Clinic
Liver Disease; Alcohol-Related, Cirrhosis
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
- Conditions
- Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
- Trial name
- IMPACT (NCT05548452)
- Testing
- Intestinal Microbiota Transplant (IMT) Capsules
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Liver Cirrhosis
Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial
Liver disease is the only common cause of death that is increasing in numbers. Once people develop severe scarring (cirrhosis), there are no medications proven to help them live longer, healthier lives.
- Trial name
- APEACH (NCT07726693)
- Testing
- Apixaban 2.5 mg twice daily
- Volunteers
- 1,142 people
- Sponsor
- University College, London
Alcoholic Hepatitis
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
Background: Alcoholic liver disease is one of the most important causes of chronic liver disease in this country. There is currently no treatment for chronic alcoholic liver disease other than abstinence.
- Trial name
- RCT SAMe (NCT00851981)
- Testing
- SAMe
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Loma Linda University
Liver Failure, Hepatitis B
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
This study evaluates the Granulocyte colony-stimulating factor (G-CSF) in the treatment of Acute on Chronic Liver Failure in adult.
- Conditions
- Liver Failure, Hepatitis B, Alcoholic Liver Disease
- Trial name
- NCT02331745
- Testing
- Granulocyte colony-stimulating factor, standard treatment
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Beijing 302 Hospital
Alcoholic Liver Cirrhosis
The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis
Background \& Aim: Bone marrow derived mesenchymal stem cells (BM-MSCs) have capacity to differentiate into hepatocytes and anti-fibrotic effect in the experimental model.
- Trial name
- NCT01741090
- Testing
- mesenchymal stem cell injection
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Yonsei University
Alcohol Use Disorder, Alcohol Associated Liver Disease
A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease
This study seeks to develop and test a novel digital pill system (DPS) that measures real-time medication ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention to provide personalized, data-driven…
- Conditions
- Alcohol Use Disorder, Alcohol Associated Liver Disease, Medications for Alcohol Use Disorder, Behavioral Medicine
- Trial name
- NCT07553377
- Testing
- AcamproSync
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University